

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3510509/publications.pdf>

Version: 2024-02-01

38  
papers

623  
citations

687335

13  
h-index

610883

24  
g-index

40  
all docs

40  
docs citations

40  
times ranked

1098  
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure-Based Design of Melanocortin 4 Receptor Ligands Based on the SHU-9119-hMC4R Cocrystal Structure. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 357-369.	6.4	12
2	Using conformational constraints at position 6 of Angiotensin II to generate compounds with enhanced AT2R selectivity and proteolytic stability. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 43, 128086.	2.2	1
3	Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors. <i>RSC Medicinal Chemistry</i> , 2021, 12, 828-870.	3.9	16
4	Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure-Activity Relationship Studies. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12929-12941.	6.4	13
5	Neuromedin U and Structural Analogs: An Overview of their Structure, Function and Selectivity. <i>Current Medicinal Chemistry</i> , 2020, 27, 6744-6768.	2.4	7
6	Neurotensin Analogues Containing Cyclic Surrogates of Tyrosine at Position 11 Improve NTS2 Selectivity Leading to Analgesia without Hypotension and Hypothermia. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4535-4544.	3.5	18
7	Trifluoromethylated Proline Surrogates as Part of $\alpha$ -Pro-Turn-Inducing Templates. <i>ChemBioChem</i> , 2019, 20, 2513-2518.	2.6	13
8	Synthesis and <i>in Vitro</i> Evaluation of Stabilized and Selective Neuromedin U-1 Receptor Agonists. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 496-501.	2.8	9
9	Indoloazepinone-Constrained Oligomers as Cell-Penetrating and Blood-Brain-Barrier-Permeating Compounds. <i>ChemBioChem</i> , 2018, 19, 696-705.	2.6	8
10	Development of potent and proteolytically stable human neuromedin U receptor agonists. <i>European Journal of Medicinal Chemistry</i> , 2018, 144, 887-897.	5.5	13
11	Efficient One-Pot Access to Trisubstituted 2-Benzazepin-3-ones as Constrained Pseudopeptide Analogues and Privileged Scaffolds. <i>Medicinal Chemistry</i> , 2018, 14, 400-408.	1.5	0
12	Cyclisation To Form Small, Medium and Large Rings by Use of Catalysed and Uncatalysed Azide-Alkyne Cycloadditions (AACs). <i>European Journal of Organic Chemistry</i> , 2017, 2017, 4678-4694.	2.4	20
13	Analgesic Properties of Opioid/NK1 Multitarget Ligands with Distinct <i>in Vitro</i> Profiles in Naive and Chronic Constriction Injury Mice. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2315-2324.	3.5	30
14	Hydrazone Linker as a Useful Tool for Preparing Chimeric Peptide/Nonpeptide Bifunctional Compounds. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 73-77.	2.8	25
15	$\beta$ -Space Screening of Dermorphin-Based Tetrapeptides through Use of Constrained Arylazepinone and Quinolinone Scaffolds. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1177-1182.	2.8	4
16	Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3777-3792.	6.4	36
17	Side Chain Cyclized Aromatic Amino Acids: Great Tools as Local Constraints in Peptide and Peptidomimetic Design. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10865-10890.	6.4	35
18	Synthesis and binding characteristics of [3H]neuromedin N, a NTS2 receptor ligand. <i>Neuropeptides</i> , 2016, 57, 15-20.	2.2	3

#	ARTICLE	IF	CITATIONS
19	Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist $\hat{\epsilon}$ “ Neurokinin-1 antagonist peptidomimetics. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 64-77.	5.5	27
20	Structural basis for bifunctional peptide recognition at human $\hat{\iota}$ -opioid receptor. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 265-268.	8.2	151
21	Azepinone-Containing Tetrapeptide Analogues of Melanotropin Lead to Selective $\hat{h}$ MC4R Agonists and $\hat{h}$ MC5R Antagonist. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 192-197.	2.8	13
22	Dual Alleviation of Acute and Neuropathic Pain by Fused Opioid Agonist-Neurokinin 1 Antagonist Peptidomimetics. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 1209-1214.	2.8	20
23	T3P-Promoted, Mild, One-Pot Syntheses of Constrained Polycyclic Lactam Dipeptide Analogues via Stereoselective Pictet $\hat{\epsilon}$ “Spengler and Meyers Lactamization Reactions. <i>Organic Letters</i> , 2015, 17, 4482-4485.	4.6	13
24	Neuropeptide FF receptors as novel targets for limbic seizure attenuation. <i>Neuropharmacology</i> , 2015, 95, 415-423.	4.1	4
25	Presence and regulation of insulin-regulated aminopeptidase in mouse macrophages. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2014, 15, 466-479.	1.7	11
26	In Vitro Membrane Permeation Studies and in Vivo Antinociception of Glycosylated Dmt <sup>1</sup> -DALDA Analogues. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 352-357.	2.8	11
27	Highly stereoselective one-pot construction of trisubstituted tetrahydro- $\hat{\iota}^2$ -carboline-fused diketopiperazines: a synthetic route towards cialis analogues. <i>RSC Advances</i> , 2014, 4, 38159-38163.	3.6	17
28	In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera. <i>Molecular Brain</i> , 2012, 5, 4.	2.6	28
29	Maillard Glycation of Peptides Containing the (N $\hat{\iota}$ His)Ac Chelator for <sup>99m</sup> Tc(CO) <sub>3</sub> Labeling. <i>International Journal of Peptide Research and Therapeutics</i> , 2006, 12, 197-202.	1.9	8
30	Synthesis and Evaluation of the $\hat{\iota}^2$ -Turn Properties of 4-Amino-1,2,4,5-tetrahydro-2-benzazepin-3-ones and of Their Spirocyclic Derivative. <i>European Journal of Organic Chemistry</i> , 2006, 2006, 2899-2911.	2.4	21
31	Synthesis and binding properties of endomorphin-2 analogs containing $\hat{\iota}$ -hydroxymethyl amino acids. <i>International Journal of Peptide Research and Therapeutics</i> , 2000, 7, 93-96.	0.1	6
32	Title is missing!. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 383-385.	0.1	1
33	Side reactions in the preparation of 1,2,3,4-tetrahydro- $\hat{\iota}^2$ -carboline-3-carboxylic acid. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 121-123.	0.1	0
34	$\hat{\iota}$ -Bn-o-AMPA as a cis peptide bond mimic in somatostatin analogues. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 67-70.	0.1	0
35	$\hat{\iota}$ -Bn-o-AMPA as a cis peptide bond mimic in somatostatin analogues. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 67-70.	0.1	1
36	Side reactions in the preparation of 1,2,3,4-tetrahydro- $\hat{\iota}^2$ -carboline-3-carboxylic acid. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 121-123.	0.1	1

#	ARTICLE	IF	CITATIONS
37	Biological consequences of the incorporation of amphiphilic amino acids into opioid peptide sequences. International Journal of Peptide Research and Therapeutics, 1998, 5, 383-385.	0.1	5
38	Conformation of two somatostatin analogues in aqueous solution. Study by NMR methods and circular dichroism. FEBS Journal, 1989, 185, 371-381.	0.2	16